Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon

By Pharmaceutical Processing | March 8, 2011

Vanda Pharmaceuticals Inc., announced
today that the European Commission (EC) has granted orphan drug designation for
tasimelteon, an oral dual melatonin receptor agonist in Phase III clinical trails
for Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals with no light
perception. This follows the positive opinion on the designation that the
Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency
adopted previously in the November 2010 COMP Committee Meeting.

Orphan designation for a medicinal product by the EC
provides benefits that can take a variety of forms including tax incentives,
protocol assistance, eligibility for grants and initiatives supporting research
and development related to this orphan indication, reduction of marketing
application fees and annual fees for qualifying companies, and potential
marketing exclusivity for up to 10 years in the European Union.

“We are very pleased to receive orphan designation from
the European Commission,” said Mihael H. Polymeropoulos, M.D., President
and Chief Executive Officer of Vanda. “This status represents an acknowledgement
of the significant unmet medical need to develop and commercialize a treatment
that may alleviate sleep/wake problems in people who are totally blind with no
light perception.”  

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE